Blood cancer study seeks markers to match patients with best immunotherapy

NCT ID NCT05450367

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study analyzed data from 249 adults with blood cancers like lymphoma and leukemia who received immunotherapy. The goal was to find markers—such as patient history or lab results—that could predict who will respond well and who might have severe side effects. By identifying these clues, doctors hope to personalize treatment and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors choose the best immunotherapy for each blood cancer patient and reduce harmful side effects.
What could go wrong: This is an observational study that only looks back at existing data. It cannot prove that any marker directly causes better outcomes, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia diffuse large B-cell lymphoma hematopoietic and lymphoid system neoplasm Hodgkins lymphoma mantle cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLOOD CANCER

Contacts and locations

Locations

Assistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospital

Paris, Île-de-France Region, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.